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Abstract Patients with 1–3 brain metastases (BM) often
receive sterotactic radiosurgery (SRS) without whole brain
radiotherapy (WBRT). SRS without WBRT carries a high
rate of relapse in the central nervous system (CNS). This
trial used sunitinib as an alternative to WBRT for post-SRS
adjuvant therapy. Eligible patients with 1–3 newly diagnosed BM, RTOG RPA class 1–2, received sunitinib after
SRS. Patients with controlled systemic disease were
allowed to continue chemotherapy for their primary disease
according to a list of published regimens (therapy ? sunitinib) included in the protocol. Patients received
sunitinib 37.5 or 50 mg/days 1–28 every 42 days until
CNS progression. Neuropsychological testing and MRIs
were obtained every two cycles. The primary endpoint was
the rate of CNS progression at 6 months (PFS6) after SRS.
Fourteen patients with a median age of 59 years were
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enrolled. Primary cancers included lung 43 %, breast
21 %, melanoma 14 %. Toxicity included grade 3 or
higher fatigue in five patients and neutropenia in two
patients. The CNS PFS6 and PFS12 were 43 ± 14 and
34 ± 14 %, respectively. Of the ten patients who completed [1 neurocognitive assessment, none showed cognitive decline. Sunitinib after SRS for 1–3 BM was well
tolerated with a PFS6 of 43 %. The prevention of progressive brain metastasis after SRS requires the incorporation of chemotherapy regimens to control the patient’s
primary disease. Future trials should continue to explore
the paradigm of secondary chemoprevention of BM after
definitive local therapy.
Keywords Sunitinib  Stereotactic radiosurgery  Brain
metastases  Secondary prevention  Neuropsychological
testing  Phase 2

Introduction
Brain metastasis is a common and devastating complication of systemic malignancies that occurs in up to 25 % of
patients with cancer [1]. The cancers that most commonly
cause brain metastasis include lung, breast, melanoma, and
kidney [2]. The incidence of brain metastasis is rising in
recent years due to improved systemic therapy and longer
survival times allowing the development of central nervous
system (CNS) metastasis. The median overall survival
(OS) for patients with brain metastases (BM) is approximately four to 6 months [3]. Prognostic factors include
performance status, age, and systemic disease control [4].
Treatment for brain metastasis has traditionally involved
whole brain radiotherapy (WBRT) to control progression
and to preserve neurologic function [5]. For patients with a
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limited number of BM (1–3 metastases), local therapy
using surgery or stereotactic radiosurgery (SRS) in addition
to WBRT improves time to neurologic deterioration,
relapse rate and OS [6, 7]. In patients who receive local
therapy with either surgery or SRS, adjuvant WBRT
improves relapse rate but not time of neurologic independence or survival when compared to no further treatment
[8, 9]. A more recent secondary post hoc analysis of the
data by Aoyama did demonstrate an OS benefit for good
prognosis patients (diagnosis-specific Graded Prognostic
Assessment 2.4–4.0) treated with SRS with WBRT compared to those who received SRS alone [10]. The CNS
progression free survival rate at 6 months after SRS alone
is approximately 50 % [8]. These data support the need for
additional therapy to control or prevent brain disease after
SRS to maintain regional (i.e., CNS) and local (site of SRS)
control of disease. Due to concerns about neurologic consequences of WBRT, however, a substantial number of
patients and physicians opt to delay WBRT until the time
of CNS progression. Hence strategies that employ targeted
therapy that may prevent new BM are urgently needed.
This trial offered an alternative treatment for this patient
subgroup and used as its primary endpoint the rate of CNS
progression at 6 months following SRS. Patients who
develop BM frequently have stable systemic disease
maintained by a systemic treatment regimen (e.g., breast
cancer patients on trastuzumab). In that setting, patients are
most often continued on the systemic regimen for ongoing
control of disease outside the CNS.
The efficacy of chemotherapeutic agents for malignancies in the brain has been limited and their use restricted to
relatively chemo-sensitive cancer types. This is partly
because the CNS has been regarded as a sanctuary site,
with the blood–brain barrier (BBB) impeding chemotherapies from reaching their CNS targets. Antiangiogenic
agents, however, do not need to cross the BBB as they
target vasculature on the abluminal side of the BBB. In
addition, such agents might be effective in the prevention
of outgrowth of microscopic BM.
Recent developments in targeted, small-molecular
agents have rendered possible the treatment of cancers
previously thought to be chemo-resistant. Sunitinib inhibits
serine/threonine kinases of the receptors for plateletderived growth factor and vascular endothelial growth
factor [11]. Sunitinib inhibits oncogenic pathways originating from these hypoxia-inducible receptors and interrupts tumor angiogenesis, proliferation, and metastasis.
Preclinical studies have suggested that BM have altered
expression of VEGF [12, 13]. Sunitinib therefore could
potentially control tumor proliferation by targeting this
pathway. While the role of this class of drugs has not been
established in the setting of BM, their pharmacologic target
and their relatively low toxicity profile in comparison to
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cytotoxic chemotherapy drugs makes their use in this group
of heterogeneous diseases attractive.

Methods
This phase II trial included patients with 1–3 BM treated
with SRS at the Cleveland Clinic or the Henry Ford
Hospital System. Subjects received sunitinib as an alternative to WBRT. We hypothesized that sunitinib therapy
after SRS would decrease the 6-month rate of brain failure
to 35 % compared to historical controls of 50 % with
WBRT [8]. The primary endpoint of the study was the CNS
6-month progression-free survival rate in patients with 1–3
BM treated with SRS followed by sunitinib. Secondary
endpoints included neurocognitive function, the 12-month
local failure rate, the median time to CNS disease progression, the overall survival (OS), and the time to systemic disease progression and the safety of sunitinib in this
patient population.
The inclusion criteria included histologically confirmed
carcinoma with 1–3 newly diagnosed CNS metastases
amenable to stereotactic radiosurgery. Patients could enroll
up to 1 month after SRS provided they could undergo the
required neurocognitive function evaluation (NCF) before
beginning treatment. Other eligibility criteria included age
C18 years, life expectancy greater than 6 weeks, Karnofsky performance status C70 (RTOG RPA class I or II). Lab
requirements: AST, ALT B 2.5 9 upper limit of normal
(ULN), total bilirubin B1.5 9 ULN, absolute neutrophil
count (ANC) C1500/lL, platelets C100,000/lL, hemoglobin C9.0 g/dL (transfusion permitted), calcium
B12.0 mg/dL and creatinine B2.5 mg/dL. Patients with
stable systemic disease on systemic therapy were permitted
to continue chemotherapy upon study entry provided there
was safety record of the systemic regimen in combination
with sunitinib. Sexually active women of childbearing
potential and sexually active men agreed to use adequate
contraception before and during study treatment. Patients
with hematuria from a primary renal tumor were eligible.
Blood pressure needed to be controlled (\160/90 mmHg,
antihypertensive medications were allowed).
Exclusion criteria included prior cranial external beam
radiation therapy, hepatic enzyme inducing antiepileptic
agents, prior sunitinib, BM from lymphoma or small cell
lung cancer, or presence of leptomeningeal metastases.
Other exclusion criteria included CNS complications
requiring urgent neurosurgical intervention (e.g., resection,
shunt placement), unresolved bowel obstruction; concomitant therapeutic dose warfarin-containing agents (e.g.,
CoumadinÒ); pregnant or nursing women, or patients with
evidence of bleeding diathesis or coagulopathy, myocardial
infarction, severe/unstable angina, severe peripheral
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vascular disease (claudication) or procedure on peripheral
vasculature, coronary/peripheral artery bypass graft, New
York Heart Association grade II or greater congestive heart
failure, cerebrovascular accident or transient ischemic
attack, clinically significant bleeding, deep venous thrombosis or pulmonary embolism within the 6 months prior to
study entry.
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high risk of baseline NCF deficits. For each subject, the
difference between the pre-treatment baseline and each
follow-up assessment was coded (according to the RC
index) as 1 (deterioration), 2 (no change), or 3 (improved).
Cross tabulations between this variable, time, and treatment group (to account for multi-arm studies) were used to
examine the percentages of patients in each treatment
group that showed meaningful losses or gains in the various test domains over the course of the study.

Treatment
Patients received sunitinib 37.5 mg daily for 4 weeks followed by a 2-week rest for a 6-week cycle. Patients who
tolerated this dose were allowed to increase the dose to
50 mg once daily. Patients who received sunitinib without
concurrent chemotherapy were allowed to start sunitinib at
50 mg once daily. Patients were permitted to receive erythropoietic agents for anemia or bisphosphonates for
hypercalcemia and/or bone metastases as needed. Antiemetics, transfusions, pyridoxine (vitamin B6; for treatment of hand-foot syndrome) were permitted. Investigators
were recommended to avoid the concurrent use of agents
that induce or inhibit CYP3A4.
The patient’s systemic assessment and chemotherapy
were managed at the discretion of the treating medical
oncologist. Patients were permitted to receive chemotherapy included on a list of combinations with sunitinib for
which peer-reviewed safety data were available at the time
this trial was designed. This list of regimens was included
in the protocol and is included in the Supplemental
Material.

Duration of therapy
Treatment continued until one of the following: disease
progression, intercurrent illness that prevented further
treatment, unacceptable adverse event(s), patient withdrawal of consent, treatment delays of [2 weeks due to
adverse events, or changes in the patient’s condition that in
the judgment of the investigator made the patient unacceptable for further treatment.

Dose adjustments
Dose reductions to 25 mg/day and then to 12.5 mg/day
were allowed, depending on the type and severity of sunitinib-related toxicity encountered. Specifically, patients
who experienced grade 3 toxicities were allowed to resume
drug with a dose reduction if the toxicity improved to grade
0–1 within 2 weeks. If, however, vascular toxicity occurred,
drug was discontinued permanently.

Neuropsychological testing

Response criteria

Neurocognitive function was assessed in several domains,
including memory (Hopkins verbal learning test) [14],
verbal fluency (Controlled Oral Word Association Test)
[15], visual-motor speed (Trail making test, Part A) [16],
executive function (Trail making test, Part B) [16], and
motor dexterity (Lafayette Grooved Pegboard) [16]. The
NCF evaluation was administered by trained technicians
and research nurses, who were certified in the administration of the test battery by a neuropsychologist. NCF was
performed at baseline and repeated every-other cycle for
duration of treatment. The difference between the pretreatment baseline and follow-up assessment scores were
determined by the reliable change (RC) index, derived
from the standard error of measurement (SEM) for each
test in the battery [17]. The advantage of using this statistical method is that the baseline level of performance of
a given individual is accounted for, since the presence of
BM in these patient’s at baseline and prior SRS confers a

Standard response criteria utilized MRI/CT scans and
neurologic examinations to determine the response to
therapy. The modified McDonald criteria were used to
assess response. Complete response (CR) was defined as
complete disappearance of all tumor on MRI/CT scan, off
all glucocorticoids with a stable or improving neurologic
examination for C4 weeks. Partial response (PR) was
defined as C50 % reduction in tumor size on bi-dimensional measurements on MRI/CT scan, on a stable or
decreasing dose of glucocorticoids, with a stable or
improving neurologic examination C4 weeks. Progressive
disease (PD) was defined as progressive neurologic
abnormalities not explained by causes unrelated to tumor
progression (e.g., anticonvulsant or corticosteroid toxicity,
electrolyte abnormalities, hyperglycemia, etc.) or C25 %
increase in the size of the tumor by MRI/CT scan or the
emergence of new brain or leptomeningeal metastases. If
neurologic status deteriorated on a stable or increasing dose
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of steroids, or if new lesions appeared on serial MRI/CT,
study treatment was discontinued. For patients who had
radiographic worsening only at the site treated by SRS,
ancillary imaging (PET scan; perfusion scan, MRS) or
tissue confirmation was required to define disease progression. Stable Disease (SD) was defined as clinical status
and MRI/CT measurements not meeting the criteria for CR,
PR or PD and confirmed after C6 weeks.
Local failure was defined as disease progression at site
of SRS. Regional failure was defined as disease progression in brain but not at site(s) of SRS. 6-month CNS
progression free survival rate—the percentage of subjects surviving at least 6 months from SRS without
progressive disease anywhere in the brain (local or
regional failure). OS was measured from SRS until death
due to any cause (all-cause mortality). Time to progression (TTP) for all sites of disease was measured from
SRS until the earliest date of progression (systemic or
CNS) or death due to any cause. Rate of local versus
regional failure was defined as rate of progression at site
of SRS (local failure) versus progression anywhere else
in CNS (regional failure).
Event-free survival was measured from SRS until disease progression or death due to any cause (all-cause
mortality). Six month OS rate was defined as the percentage of subjects surviving at least 6 months from SRS.
Safety and tolerability were assessed based on adverse
events, hematological and nonhematological toxicities.

Statistical methods
Historically the 6-month CNS progression-free survival
rate in patients with 1–3 BM treated with SRS alone is
approximately 50 % [8]. 47 eligible and evaluable patients
were to be treated in the present trial in order to have
statistical power [.80 to detect an increase in the 6-month
CNS progression-free survival rate to 65 %. This estimate
was based on a 2-sided p = 0.05 statistical test and
assumed that progression-free survival would follow an
exponential distribution. Assuming 10 % of patients were
not evaluable, five additional patients were planned for a
goal of 52 patients to be enrolled on the study. PFS and OS
were summarized using the Kaplan–Meier method. Changes in NCF from pre-treatment were analyzed using paired
t tests and the sign test.

Results
Between August 2009 and June 2011, fourteen patients
(Table 1) including six males (43 %) with the median age
59 years (range 46–80 years) enrolled on the study. Due to

123

J Neurooncol (2015) 124:485–491
Table 1 Characteristics of patients
Factor

N (%)

Gender
Male

6 (43 %)

Age—median (range)

59 (46–80)

Primary
Lung

6 (43 %)

Breast

3 (21 %)

Melanoma

2 (14 %)

Other (1 each)

3 (21 %)

RPA class
1

4 (29 %)

2
Number of metastases

10 (71 %)

1

6 (43 %)

2

5 (36 %)

3

3 (21 %)

slow accrual this trial was stopped prematurely. Primary
cancer of the patients treated with sunitinib included six
lung cancer (43 %), three breast cancer (21 %), two melanoma (14 %), one renal cell cancer (7 %), one uterine
carcinoma, and one cervical cancer. Four patients were
RPA class 1 and ten patients were RPA class 2. Six patients
had one BM, five had two BM and three patients had three
BM.
The regimen had manageable toxicities that included
grade C3 fatigue in five patients, neutropenia in two
patients and additional toxicities in one patient each
(Table 2). Two patients required dose reduction from
50 mg daily to 37.5 mg daily for grade 3 toxicities; one
had fatigue and generalized weakness and the other had
fatigue and rash.
The CNS PFS6 and PFS12 were 43 ± 14 and
34 ± 14 %, respectively (Table 3; Fig. 1). The median
PFS was 4.8 months (95 % CI 1.5–13). Secondary endpoints included a median OS of 11.7 months (95 % CI
3.7–31) and OS12 of 50 ± 13 %.

Table 2 Grade 3–4 treatment related toxicity
Toxicity

N (%)

Gr 3

Gr 4

Fatigue

5 (36)

5

0

Neutropenia

2 (14)

1

1

Hemolysis

1 (7)

1

0

Lymphopenia

1 (7)

0

1

Mucositis/stomatitis

1 (7)

1

0

Generalized muscle weakness

1 (7)

1

0

Rash

1 (7)

1

0

J Neurooncol (2015) 124:485–491

489

Table 3 Outcomes of patients

Table 4 Baseline neurocognitive function

CNS PFS6

43 ± 14 %

CNS PFS12

34 ± 14 %

CNS PFS (median)

4.8 mo (95 % CI 1.5–13)

OS (median)

11.7 mo (95 % CI 3.7–31)

Memory—learning

4

29

50 ± 13 %

Memory—delayed recall

3

21

Language

3

21

OS12

Domain

Impairment (n = 14)
Number

Percent

Processing speed

7

50

Executive

5

36

Any impairment

9

64

Table 5 Neurocognitive function
Domain

Increase

Stable

Decrease

Memory—learning

1 (10 %)

7 (70 %)

2 (20 %)

Memory—delayed recall

1 (10 %)

6 (60 %)

3 (30 %)

Language

3 (30 %)

6 (60 %)

1 (10 %)

Processing speed

4 (40 %)

6 (60 %)

-0-

Executive

3 (30 %)

4 (40 %)

3 (30 %)

Discussion
Fig. 1 Freedom from CNS progression and overall survival of
patients treated with sunitinib

Neurocognitive function
Sixty-four percent of the patients showed impaired neurocognitive function at the baseline assessment, defined as
1.5 SD below mean on C2 tests or two SD below mean on
C1 test (Table 4). Ten of the 14 patients completed at least
one post-treatment NCF battery at an interval of approximately 2 months. There were no significant changes in any
cognitive domain in this group (all p’s [ 0.05; Table 5).
Individual analysis of reliable change (RCI) scores showed
no evidence of improvement or decline (p’s [ 0.05) while
on treatment with sunitinib.
Only 5 of the 14 patients completed [1 follow up
neurocognitive assessment, with the treatment duration
ranging from 5 to 16 months (Table 6). Although a statistical analysis of this small number of subjects is not
considered to be meaningful, a qualitative evaluation of
the data was conducted. Although the number of patients
is small, based on the RCI methodology 4/5 patients
showed improvement in verbal fluency at the last followup compared to baseline and 3/5 patients showed
improvement in verbal memory. On no test was the
number of subjects declining greater than the number
showing improvement.

This phase II trial used sunitinib instead of WBRT for
secondary prevention of further BM after SRS. The study
demonstrated progression free disease control at 6 months
in 43 % of subjects, not significantly different from historical rates of control when WBRT is used after SRS.
Sunitinib was found to have an acceptable safety profile
with a low rate of grade 4 toxicities. Most grade 3 toxicities
were managed and two patients were removed from the
study due to adverse events/side effects. These safety
parameters also demonstrate the safety profile of combination of sunitinib with a variety of systemic treatment
regimens.
The comprehensive evaluation of NCF revealed a high
rate of baseline cognitive deficits in this population (64 %),
consistent with prior literature [18]. No substantial change
in NCF was seen in this population after at least the
2-month post-treatment time point. Further NCF analyses
were limited due to the small numbers of patients who
completed multiple follow-ups, but a preliminary analysis
showed that NCF did not decline in subjects who remained
on study without disease progression. Although preliminary given the limited number of subjects in this analysis,
the findings do not demonstrate a substantial cognitive
decline associated with treatment, a significant concern in
those treated with WBRT [19].
This study has several limitations. The small number of
subjects in the study limits generalizability of the outcome
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Table 6 Neurocognitive function in patients who completed [1
follow up neurocognitive assessment baseline versus last assessment
Domain

Increase

Stable

Decrease

Memory—learning

3 (60 %)

-0-

2 (40 %)

Memory—delayed recall

2 (40 %)

1 (20 %)

2 (40 %)

Language

4 (80 %)

-0-

1 (20 %)

Processing speed

2 (40 %)

1 (20 %)

2 (40 %)

Executive

1 (20 %)

3 (60 %)

1 (20 %)

findings. The study allowed patients with all systemic
cancers on this study with exception of lymphoma and
small cell lung cancer. Future studies should stratify for
patients with different cancers, as patients of HER2 positive BM may have a different outcome as compared to a
with BRAF positive melanoma. This trial was a pilot effort
to show feasibility of this approach for secondary prevention of BM. Molecular testing on patients’ tumors was not
required on this study and should be incorporated in future
studies with BM.
A major barrier to successful completion of clinical
trials in brain metastasis is the need to control not only
CNS disease but also systemic disease. For most drugs
considered as intervention in BM trials, no safety data exist
for the combination of the new agent with the regimen
needed to control systemic disease. A study of WBRT and
stereotactic radiosurgery followed by randomization to no
drug, temozolomide, or erlotinib closed prematurely for
poor accrual due to hesitancy on the part of the patients’
treating medical oncologists to delay systemic
chemotherapy [20]. At least three additional trials for the
primary or secondary chemoprevention of BM have closed
due to poor accrual (NCT00638963, NCT01613482, and
NCT00717275). Multiple trials have combined systemic
agents with sunitinib. These combinations were allowed as
regimens on the trial, thus giving patients and investigators
the opportunity to continue a regimen that was controlling
the systemic disease while participating in the trial. A
recent review of patients enrolled in the phase three
Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET) revealed a significantly lower BM
incidence in patients who received sorafenib (3 %) than in
those who received placebo (12 %) [21]. This report provides the first evidence that TKIs protect the brain from
metastatic RCC, which has been confirmed by others [22].
A limitation of trials of chemoprevention—primary or
secondary—of BM is the challenge of giving a desired
agent with an ongoing chemotherapy regimen that is controlling the patient’s systemic disease. Usually the agent
has not been used in combination with the regimen that is
controlling or is planned for the management of the
patient’s systemic disease. As the development of brain
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metastasis is a particularly difficult transition in a patient’s
disease trajectory, advocacy for entry onto the study by
both the radiation oncologist and the treating medical
oncologist is critical to successful clinical trial accrual.

Conclusion
This study employed sunitinib as a WBRT-sparing agent to
help control the micro metastatic disease while SRS helps
controlling the macro metastatic disease. SRS with adjuvant sunitinib is feasible combination therapy associated
with manageable toxicity as demonstrated in this cohort of
patients. Unfortunately, however, the trial did not meet its
primary objective. SRS ? chemotherapy studies for secondary prevention of BM need to incorporate a patient’s
ongoing systemic chemotherapy regimen to control their
systemic disease. In addition, future trials of this paradigm
will benefit from improved patient selection based on histology and the presence of molecular targets for which
specific drugs exist. Finally, a critical factor to promote
accrual in future studies of secondary prevention of brain
metastasis is collaboration between the patient’s medical
oncologist and radiation oncologist.
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